Prime Medicine (PRME) Amortizatization of Intangibles (2021 - 2024)
Prime Medicine's (PRME) quarterly Amortizatization of Intangibles came in at $675000.0 in Q1 2024, up 10.47% YoY from $611000.0 in Q2 2023, and down 37.96% on a QoQ basis from $1.1 million in Q4 2023.
Prime Medicine (PRME) Amortizatization of Intangibles (2021 - 2024) Analysis & Trends
Prime Medicine (PRME) has 4 years of Amortizatization of Intangibles data on file, last reported at $675000.0 in Q1 2024.
- Quarterly Amortizatization of Intangibles rose 10.47% year-over-year to $675000.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $3.5 million (up 229.41% YoY) and the FY2023 annual result came in at $3.4 million, up 1263.2% from the prior year.
- Amortizatization of Intangibles slipped to $675000.0 in Q1 2024, from $1.1 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.1 million in Q4 2023 to a low of -$715000.0 in Q4 2021.
- A 4-year average of $361800.0 and a median of $480500.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles soared 1514.29% — and 2024, when it increased 10.47%.
- Tracing PRME's Amortizatization of Intangibles over 4 years: stood at -$715000.0 in 2021, then surged by 148.95% to $350000.0 in 2022, then soared by 210.86% to $1.1 million in 2023, then sank by 37.96% to $675000.0 in 2024.
- The last three Amortizatization of Intangibles figures came in at $675000.0 (Q1 2024), $1.1 million (Q4 2023), and $917000.0 (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.33 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 678,000.00 |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 675,000.00 |
| Mar 31, 2024 | 675,000.00 |
| Dec 31, 2023 | 1.09 Mn |
| Dec 31, 2023 | 1.09 Mn |
| Sep 30, 2023 | 917,000.00 |
| Sep 30, 2023 | 917,000.00 |
| Jun 30, 2023 | 792,000.00 |
| Jun 30, 2023 | 792,000.00 |
| Mar 31, 2023 | 611,000.00 |
| Mar 31, 2023 | 611,000.00 |
| Dec 31, 2022 | 350,000.00 |
| Dec 31, 2022 | 350,000.00 |
| Sep 30, 2022 | 149,000.00 |
| Sep 30, 2022 | 149,000.00 |
| Jun 30, 2022 | -56,000.00 |
| Jun 30, 2022 | -56,000.00 |
| Mar 31, 2022 | -193,000.00 |
| Mar 31, 2022 | -193,000.00 |
| Dec 31, 2021 | -715,000.00 |
| Dec 31, 2021 | -715,000.00 |